Fulminant Liver Failure after Treatment with a Checkpoint Inhibitor for Gastric Cancer: A Case Report and Review of the Literature

Nivolumab is a promising monoclonal antibody inhibitor of programmed death-1, a protein on the surface of T-cells. As such, it is approved for use in patients with multiple advanced malignancies and can significantly elongate progression-free survival. However, monoclonal antibody inhibitors can lea...

Descripción completa

Detalles Bibliográficos
Autores principales: Dibos, Miriam, Dumoulin, Johanna, Mogler, Carolin, Wunderlich, Silke, Reichert, Maximilian, Rasch, Sebastian, Schmid, Roland M., Ringelhan, Marc, Ehmer, Ursula, Lahmer, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381004/
https://www.ncbi.nlm.nih.gov/pubmed/37510756
http://dx.doi.org/10.3390/jcm12144641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381004/
https://www.ncbi.nlm.nih.gov/pubmed/37510756
http://dx.doi.org/10.3390/jcm12144641

Ejemplares similares